IPO Profile: Nexvet Biopharma PLC

Company Details

Melbourne, Australia

61-38-459-2267

www.nexvet.com

Description: Nexvet Biopharma Pty Ltd is a Australia-based biopharma company that operates as a veterinary biologic drug developer. The company is engaged in developing medicines for companion animals, (cats, dogs and horses). The Nexvet Portfolio focuses on inflammatory disease, pain and cancer. Its products include NV-01/NV-02/NV-03, NV-04/NV-05 and NV-06/NV-07. NV-01 is a fully caninised monoclonal antibody to a target that has demonstrated clinical utility in a number of human indications involving pain. The product has emerged from its PETisation process and retains the high affinity of the parent murine-monoclonal antibody. NV-04 and NV-05 are both fully caninised monoclonal antibodies to key oncology, autoimmune and lymphoma targets that have shown potent in-vitro activity. NV-06/NV-07 will be used for the treatment of chronic inflammatory diseases, such as atopic dermatitis in dogs.

IPO Details

Exchange and Ticker: Nasdaq: NVET

Filing Range: 4.00 million shares @ $13.00 to $16.00

Date of IPO: 2/5/15

Offering Price: $10.00

Offering Size: $40M

Shares Outstanding: 11.2M

Underwriters: Merrill Lynch, Pierce, Fenner, Cowen

Co-managers: Piper Jaffray Cos, JMP Securities LLC

Company Counsel: ByrneWallace

Manager Counsel: Cooley LLP

Auditor: PricewaterhouseCoopers LLP

Market Capitalization on 2/27/15: $ 112.91M

Close price on 2/27/15: $ 10.03

Investment Details

Venture Backers:

• Tavistock Group Inc
• Foresite Capital Management LLC
• Farallon Capital Management LLC
• Intersuisse Bioscience Managers Pty Ltd
• Undisclosed investors

Financing Rounds:

• 10/28/13 $6.6M
• 4/16/14 $31.5M

Source: Data provided by Thomson Reuters.